Regeneron Pharmaceuticals, Inc. REGN

Revenue Intelligence Report • 66 quarters of SEC filing data • Updated 2026-03-15

Regeneron Pharmaceuticals, Inc. has a forecasted full-year revenue of $19B, a +30.1% year-over-year change, based on 66 quarters of SEC filing data. Key revenue drivers include R&D ($5.07 per $1) and SG&A ($5.06 per $1). The ARDL model has 23.5% MAPE.

Investment Thesis

At 23.5% MAPE, the model captures Regeneron Pharmaceuticals, Inc.'s broad revenue trajectory, though quarterly variability suggests sensitivity to external factors. Every $1 of R&D investment is associated with $5.07 of revenue, indicating efficient capital deployment in innovation. Each $1 of SG&A spending generates $5.06 in revenue, reflecting strong commercial efficiency.

Next FY Revenue
$18.7B
+30.1% YoY
R&D Multiplier
$5.07 per $1
SG&A Multiplier
$5.06 per $1
Model Accuracy
23.5% MAPE
Holdout validation: The model predicted $4.2B vs the actual $3.9B — an error of 7.9%.

Revenue Forecast

REGN Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $4.2B $3.9B $3.5B – $4.9B +10.6% ✓ In range
Q2 2026 $4.2B $3.2B – $5.2B +38.2%
Q3 2026 $4.6B $3.3B – $5.8B +24.9%
Q4 2026 $4.8B $3.3B – $6.2B +27.3%
Q1 2027 $5.1B $3.5B – $6.7B +31.2%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Regeneron Pharmaceuticals, Inc.'s systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 0.9818 -1.8% In line with trend 16
FQ2 (Dec–Feb) 1.0139 +1.4% In line with trend 16
FQ3 (Mar–May) 0.9092 -9.1% -9.1% below trend 15
FQ4 (Jun–Aug) 1.0534 +5.3% +5.3% above trend 15

How Spending Drives Revenue

REGN Spending Timing
Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. Model: ARDL (linear) with 66 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

ABBV AMGN HOLX ISRG DXCM COO WST CAH